Intel stock extends gains after report of possible U.S. government stake
Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding non-compliance with the exchange’s listing requirements. According to InvestingPro data, the stock has fallen 85.71% over the past year and is currently trading near its 52-week low. The notice, dated May 1, 2025, indicates that Rani Therapeutics does not meet the minimum Market Value of Listed Securities (MVLS) threshold of $50 million required for continued listing on The Nasdaq Global Market.
The company’s MVLS has fallen below the requisite level for 30 consecutive business days, triggering the notice from Nasdaq. With a current market capitalization of $62.66 million and a WEAK financial health score according to InvestingPro, Rani Therapeutics has been granted a 180-day period until October 28, 2025, to regain compliance. To do so, the company’s MVLS must meet or exceed $50 million for a minimum of 10 consecutive business days during this period.
If Rani Therapeutics fails to comply with the MVLS requirement by the deadline, it risks having its securities delisted from Nasdaq. However, the company would have the right to appeal the delisting decision to a Nasdaq hearings panel or seek a transfer of its securities to The Nasdaq Capital Market if it satisfies the listing requirements of that exchange.
As of now, Rani Therapeutics is evaluating potential courses of action to address the deficiency and regain compliance with Nasdaq’s continued listing standards. Despite the challenges, analyst price targets range from $5 to $14, suggesting potential upside. The company’s next earnings report is scheduled for May 7, 2025, which could provide crucial updates on its strategy. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about the company’s outlook.
This development is based on the latest 8-K filing by Rani Therapeutics Holdings, Inc. with the Securities and Exchange Commission.
In other recent news, Rani Therapeutics Holdings Inc. reported its financial results for the fourth quarter of 2024, showing a net loss of $56.6 million, an improvement from $67.9 million in 2023. The company introduced its first contract revenue of $1 million during this period. Research and development expenses decreased significantly by $12.9 million, contributing to the narrowing of the net loss. Cash reserves are projected to support operations into the third quarter of 2025.
Additionally, Stifel and BTIG research firms maintained their Buy ratings on Rani Therapeutics, with price targets of $8 and $14, respectively, citing the potential of Rani’s RT-114, a RaniPill containing a GLP-1/GLP-2 dual agonist. The RT-114 has shown promising preclinical results with improved tolerability and lower manufacturing costs, which could enhance patient adherence. Rani Therapeutics plans to initiate a Phase 1 trial for RT-114 in mid-2025, targeting obese patients with a BMI between 30 and 39.9 kg/m². The trial will focus on evaluating changes in body weight and the efficacy of the treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.